EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer

Camila Robles-Oteíza iD, Katherine Hastings iD, Jungmin Choi iD, Isabelle Sirois iD, Arvind Ravi iD, Francisco Expósito iD, Fernando de Miguel iD, James R Knight iD, Francesc López-Giráldez iD, Hyejin Choi iD, Nicholas D Socci iD, Taha Merghoub iD und 7 weitere

Journal of Experimental Medicine · 06.01.2025 · 222 (1)

DOI: 10.1084/jem.20231106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 25.11.2024. Verfasst von Camila Robles-Oteíza und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Lung Neoplasms, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: Stand Up To Cancer, NCI NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors that initially responded but eventually developed AR to anti-PD-1, alone or in combination with anti-CTLA-4. Resistant tumors harbored decreased infiltrating T cells and reduced cancer cell-intrinsic MHC-I and MHC-II levels, yet remained responsive to IFNγ. Resistant tumors contained extensive regions of hypoxia, and a hypoxia signature derived from single-cell transcriptional profiling of resistant cancer cells was associated with decreased progression-free survival in a cohort of NSCLC patients treated with anti-PD-1/PD-L1 therapy. Targeting hypoxic tumor regions using a hypoxia-activated pro-drug delayed AR to ICIs in murine Msh2 KO tumors. Thus, this work provides a rationale for targeting tumor metabolic features, such as hypoxia, in combination with immune checkpoint inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsLung NeoplasmsDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungAnimalsMiceHumansMice, KnockoutMutS Homolog 2 ProteinProgrammed Cell Death 1 ReceptorCell Line, TumorB7-H1 AntigenMice, Inbred C57BLHypoxiaCTLA-4 Antigen

Substanzen

Immune Checkpoint InhibitorsMutS Homolog 2 ProteinProgrammed Cell Death 1 ReceptorB7-H1 AntigenCTLA-4 Antigen

Autor:innen und Institutionen

  • Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Yale Cancer Center, Yale School of Medicine , New Haven, CT, USA.
  • Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
  • Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
  • CHU Sainte-Justine Research Center , Montreal, Canada.
  • Broad Institute of Massachusetts Institute of Technology and Harvard , Cambridge, MA, USA.

ORCID-Profile: Camila Robles-Oteíza, Katherine Hastings, Jungmin Choi, Isabelle Sirois, Arvind Ravi, Francisco Expósito, Fernando de Miguel, James R Knight, Francesc López-Giráldez, Hyejin Choi, Nicholas D Socci, Taha Merghoub, Mark Awad, Gad Getz, Justin Gainor, Matthew D Hellmann, Étienne Caron, Susan M Kaech, Katerina Politi

Förderung

  • Stand Up To Cancer
  • NCI NIH HHS
  • National Institute of Health
  • American Cancer Society
  • Mark Foundation For Cancer Research
  • National Research Foundation of Korea
  • American Association for Cancer Research
  • National Cancer Institute

Zitieren

APA

Robles-Oteíza, C., Hastings, K., Choi, J., Sirois, I., Ravi, A., Expósito, F., de Miguel, F., Knight, J. R., López-Giráldez, F., Choi, H., Socci, N. D., Merghoub, T., Awad, M., Getz, G., Gainor, J., Hellmann, M. D., Caron, É., Kaech, S. M., & Politi, K. (2025). Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer. Journal of Experimental Medicine, 222(1). https://doi.org/10.1084/jem.20231106

Vancouver

Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, et al. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer. Journal of Experimental Medicine. 2025;222(1). doi:10.1084/jem.20231106

BibTeX
@article{RoblesOteza2025,
  author = {Robles-Oteíza, Camila and Hastings, Katherine and Choi, Jungmin and Sirois, Isabelle and Ravi, Arvind and Expósito, Francisco and de Miguel, Fernando and Knight, James R and López-Giráldez, Francesc and Choi, Hyejin and Socci, Nicholas D and Merghoub, Taha and Awad, Mark and Getz, Gad and Gainor, Justin and Hellmann, Matthew D and Caron, Étienne and Kaech, Susan M and Politi, Katerina},
  title = {Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  volume = {222},
  number = {1},
  doi = {10.1084/jem.20231106}
}
Kostenlos starten →